StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)

Equities research analysts at StockNews.com assumed coverage on shares of Lipocine (NASDAQ:LPCN) in a note issued to investors on Friday. The brokerage set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Trading Up 2.8 %

LPCN opened at $3.30 on Friday. The stock has a market cap of $17.65 million, a price-to-earnings ratio of -4.34 and a beta of 1.42. Lipocine has a 1 year low of $2.91 and a 1 year high of $11.79. The stock has a fifty day moving average price of $3.98 and a 200 day moving average price of $4.53.

Institutional Trading of Lipocine

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC lifted its stake in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 57,464 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,248 shares during the quarter. Geode Capital Management LLC owned about 1.07% of Lipocine worth $280,000 as of its most recent filing with the SEC. Institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.